The new ADA /EASD Management of Hyperglycemia in Type 2 Consensus Statement 2022 was just released.
Which of the following is an accurate recommendation according to these updated guidelines?
- Initiate treatment with metformin for most individuals, including those with cardiovascular disease.
- If A1C not at target with 2 or more oral agents, add on basal insulin therapy.
- Avoid the use of SGLT-2 Inhibitors in those with an eGFR of less than 25.
- Prioritize the use of organ protective medications in those with cardiorenal disease.
Click Here to Test your Knowledge
Want to learn more about this question? Join us for our
Meds for Type 2 Update
Level 2
Plan on joining this exciting webinar that walks participants through the newly released, “Management of Hyperglycemia in Type 2 Consensus Report by the ADA and EASD”. She will highlight the revised guidelines with a focus on new elements and exciting changes on how we approach medication management for type 2 diabetes. Together, we will explore clinical factors to consider when determining the best strategy to improve glucose management in people with type 2 diabetes and other co-conditions. There will be a special focus on cardiovascular risk reduction and renal protection and addressing clinical inertia.
Objectives:
- Describe the role of Diabetes Care and Education Specialists in advocating for optimal therapeutic approaches.
- Discuss the application of the new ADA/EASD Guidelines to improve glucose and reduce CV and renal risk.
- List strategies to initiate and adjust oral and injectable therapy using a person-centered approach
Intended Audience: A great course for health care professionals seeking evidence-based information that improves the quality of life and outcomes.
Don’t worry if you can’t make it live. Your registration guarantees access to the recorded version in the Online University.
